Identifying MPN-Specific Immune Targets in Blood and Bone Marrow

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects blood and bone marrow samples from adults with myeloproliferative neoplasms (including PV, ET, PMF, and related conditions) and compares them with samples from healthy donors. Researchers will look for T cells in the bone marrow that can recognize MPN cells and identify the antigens and TCRs involved. The goal is to find immune targets that could inform future immune-based therapies for MPN. No intervention is involved; samples are used for laboratory analyses to understand immune responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.
* Patients not previously diagnosed with a haematological disease as controls

Exclusion Criteria:

* Patients with any other hematological malignancy.

Where it's running

• de Duve Institute, UCLouvain
  Brussels, Woluwe, Belgium Recruiting

Study contacts

• Study coordinator: Sophie Lucas
• Email: sophie.lucas@uclouvain.be
• Phone: 0032 (0)2 436 23 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Orally administered JBI-802 in certain blood cancers with high platelets

  This study tests whether taking JBI-802 by mouth can be safe and helpful for adults with essential thrombocythemia or related blood cancers that involve high platelet counts.

  Recruiting at 7 sites Phase 1/2 Jubilant Therapeutics Inc. · Sydney, New South Wales and 6 other locations · NCT07612280

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• PRT12396 for people with high-risk polycythemia vera or myelofibrosis

  The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.

  Recruiting at 22 sites Phase 1 Prelude Therapeutics Incorporated · Los Angeles, California and 21 other locations · NCT07469891

• Pelabresib plus ruxolitinib for adults with myelofibrosis

  This trial will see if adding pelabresib to ruxolitinib helps adults with primary myelofibrosis or post‑PV/post‑ET myelofibrosis who have not previously taken JAK inhibitor therapy.

  Recruiting at 165 sites Phase 3 Novartis · Denver, Colorado and 164 other locations · NCT07357727

• Post-transplant cyclophosphamide strategies to prevent graft-versus-host disease after mismatched unrelated donor stem cell transplant

  This platform tests whether adding different drug combinations with post-transplant cyclophosphamide prevents graft‑versus‑host disease better than the standard regimen for adults getting mismatched unrelated donor peripheral blood stem cell transplants for blood cancers.

  Recruiting at 13 sites Phase 2 Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 12 other locations · NCT06859424

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.